Related Experiment Video
Updated: Jan 18, 2026

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma
Published on: October 14, 2016
Rhabdomyosarcoma in Pediatric Patients Under 2 Years: Clinical Features and Outcome
Mohammad Alzoubi1, Adam Diab1, Nada Odeh1
1School of Medicine.
Insights
Infants with rhabdomyosarcoma (RMS) have poorer outcomes. This study found that children under 2 with RMS face high recurrence rates and suboptimal survival, necessitating tailored treatments.
Area of Science:
- Pediatric Oncology
- Cancer Research
- Clinical Pediatrics
Background:
- Rhabdomyosarcoma (RMS) in children 1-9 years old typically has a good prognosis.
- Infants with RMS may have worse outcomes due to less aggressive local therapy to avoid long-term effects.
- This study focuses on the unique challenges of RMS in children under 2 years old.
Purpose of the Study:
- To investigate the clinical characteristics of rhabdomyosarcoma (RMS) in infants.
- To analyze the treatment approaches for RMS in children under 2.
- To determine the survival outcomes for this specific pediatric population.
Main Methods:
- Retrospective review of 34 pediatric RMS cases diagnosed between 2002-2022.
- Analysis of demographics, clinical features, and treatment data.
- Survival analysis using Kaplan-Meier methods and multidisciplinary team review.
Main Results:
- The median age was 13 months; 70.6% were male. Bladder/prostate (38%) and orbit (14.7%) were common sites.
- Embryonal subtype predominated. Metastasis occurred in 17.6%. 5-year event-free and overall survival rates were 55.1% and 57.5%.
- Local relapse was common. TNM stage, clinical group, metastasis, and radiotherapy use impacted survival.
Conclusions:
- Children under 2 with RMS experience significant challenges, including high local recurrence rates.
- Survival outcomes for infants with RMS are suboptimal compared to older children.
- Tailored treatment strategies are crucial to balance effective local control and minimize long-term toxicity.
Background:
Rhabdomyosarcoma (RMS) typically responds well to a combination of treatments with favorable prognosis in children 1 to 9 years old. However, infants may fare worse due to receiving less aggressive local therapy for concerns about long-term effects of surgery/radiation. This study investigates the clinical characteristics, treatment approach, and survival outcomes of RMS in children under 2.
Methods:
We reviewed retrospectively children younger than 2 years with newly diagnosed RMS treated from January 2002 until December 2022 at King Hussein Cancer Center. Demographics, clinical characteristics, and outcomes were analyzed. Statistical analysis included descriptive statistics and survival analysis using Kaplan-Meier methods. All cases were reviewed in a multidisciplinary clinic comprising experienced radiotherapists and surgeons.
Results:
We identified 34 cases of RMS in patients younger than 2 years at diagnosis. The median age was 13 months, with 70.6% males. The most common tumor site was bladder/prostate (N=13, 38%), followed by orbit (N=5, 14.7%), the predominant subtype was embryonal (N=30). Risk-stratification categorized 17.6% as low-risk and 79.4% as intermediate-risk. Twenty-five patients had tumors >5 cm, with metastasis in 6 (17.6%). All patients received neo-adjuvant chemotherapy, local control was by radiotherapy only (n=12, 35.3%), combined surgery and radiotherapy (n=11, 32.4%), or surgery alone (n=3, 8.8%). The 5-year event-free and overall survival rates were 55.1% and 57.5%, respectively. Fourteen patients experienced relapse/progression, with local relapse the most common pattern. TNM stage, clinical group, metastasis at diagnosis, and radiotherapy use significantly impacted survival.
Conclusions:
Children under 2 years of age with RMS face significant challenges, with high local recurrence rates and suboptimal survival outcomes compared with older pediatric patients. Our findings highlight the need for tailored treatment approaches that balance effective local control with minimizing long-term toxicity.
Related Concept Videos
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Pharmacokinetics in Pediatric Patients: Drug Excretion
Pharmacokinetics in Pediatric Patients: Drug Distribution
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Esophageal Strictures-II: Clinical Features and Management
Healthcare providers should gather a comprehensive medical history and conduct a physical examination for diagnosis. If esophageal stricture is...

